Literature DB >> 2988597

Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders.

B Stollmann, C Fonatsch, W Havers.   

Abstract

This report deals with myeloproliferative disorders associated with chronic, persistent Epstein-Barr virus (EBV) infection and with monosomy 7 and aberrations concerning chromosomes 3 and 5. Altogether five children were affected, their age ranging from 1 to 4 years at time of clinical diagnosis. Principal symptoms were: hepatomegaly, splenomegaly, recurring upper respiratory tract infection and anaemia. The serum IgG level remained persistently increased. Anti EBV antibody concentrations were measured over a period of 9 months to 6 years, demonstrating persistently increased concentrations of IgG antibodies to viral capsid antigen (VCA) and against early antigen (EA). In three patients IgA antibodies were also studied and were found to be elevated. Within 2-5 years two children developed chronic myelomonocytic leukaemia from the chronic myeloproliferative syndrome. A third patient who initially was diagnosed as chronic myelomonocytic leukaemia developed acute leukaemia within a period of 12 months. A fourth patient with myeloproliferative syndrome went into spontaneous remission after an observation period of 2 years. A fifth patient, the only one with translocation t(3;5)(q27;q33), displayed symptoms and a clinical course that can best be characterized as juvenile chronic myelocytic leukaemia. The clinical, haematological, serological and cytogenetic findings may be related.

Entities:  

Mesh:

Year:  1985        PMID: 2988597     DOI: 10.1111/j.1365-2141.1985.tb07399.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Chronic granulocytic leukemia in children.

Authors:  G Garewal; R K Marwaha; N Marwaha; R Sarode; D Prakash
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

2.  Twenty-three cases of acute lymphoblastic leukemia with translocation t(4;11)(q21;q23): the implication of additional chromosomal aberrations.

Authors:  C Schoch; H Rieder; M Freund; D Hoelzer; H Riehm; C Fonatsch
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

3.  Establishment and characterization of a novel CD34-positive human myeloid leukemia cell line: MHH225 growing in serum-free culture.

Authors:  H T Hassan; E Petershofen; E Lux; C Fonatsch; G Heil; M Freund
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

4.  Translocation of c-abl oncogene and PDGFB (c-sis) gene in a case of CML with 46,XY, t(22;22).

Authors:  G Gradl; H Tesch; G Schwieder; T Wagner; C Fonatsch
Journal:  Blut       Date:  1989-06

5.  Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.

Authors:  Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

6.  Myeloproliferative disease in children: a demographic study.

Authors:  M M Reid; P W Saunders; J Kernahan
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

7.  Highly refractory acute myeloid leukemia.

Authors:  Wolfgang Füreder; Martin Filipits; Wolfgang R Sperr; Birgit Kainz; Ulrich Jäger; Christa Fonatsch; Ilse Schwarzinger; Oskar A Haas; Robert Pirker; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

8.  Cytogenetic markers in hematoproliferative disorders.

Authors:  C Fonatsch
Journal:  Blut       Date:  1985-11

9.  The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species.

Authors:  Bettina Gruhne; Ramakrishna Sompallae; Diego Marescotti; Siamak Akbari Kamranvar; Stefano Gastaldello; Maria G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.